Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
23.46
-0.42 (-1.76%)
At close: Sep 12, 2025, 4:00 PM EDT
23.92
+0.46 (1.96%)
After-hours: Sep 12, 2025, 7:58 PM EDT
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $13.82M in the quarter ending June 30, 2025, with 186.01% growth. This brings the company's revenue in the last twelve months to $199.89M, up 1,218.82% year-over-year. In the year 2024, Stoke Therapeutics had annual revenue of $36.56M with 316.34% growth.
Revenue (ttm)
$199.89M
Revenue Growth
+1,218.82%
P/S Ratio
6.74
Revenue / Employee
$1,561,664
Employees
128
Market Cap
1.29B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
Dec 31, 2022 | 12.41M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
STOK News
- 11 days ago - Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome - Business Wire
- 15 days ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 - Business Wire
- 19 days ago - Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - Business Wire
- 25 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 4 weeks ago - Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 4 weeks ago - Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Business Wire
- 5 weeks ago - Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates - Business Wire
- 5 weeks ago - Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - Business Wire